Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is in hot pursuit. The 50 mg oral semaglutide pill achieved a 15.1% weight loss in ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

The request follows a similar move by Eli Lilly ... as an option for weight loss, saying: "This can be risky for patients, as unapproved versions do not undergo FDA's review for safety ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In a fresh appearance on CNBC's Squawk on the Street, Jim Cramer cautioned ...

We could also highlight the fact that Eli Lilly's weight loss pipeline is one of the strongest in the industry. However, since analysts may have overestimated how large the weight loss market will ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.